In yesterday’s Wall Street session, AngioDynamics Inc. (NASDAQ:ANGO) shares traded at $11.40, down -0.44% from the previous session.
As of this writing, 4 analysts cover AngioDynamics Inc. (NASDAQ:ANGO). The consensus rating among analysts is ‘Overweight’. As we calculate the median target price by taking the range between a high of $26.00 and a low of $22.00, we find $24.00. Given the previous closing price of $11.45, this indicates a potential upside of 109.61 percent. ANGO stock price is now -13.45% away from the 50-day moving average and -33.20% away from the 200-day moving average. The market capitalization of the company currently stands at $451.10M.
Do You Know The Best Place To Find Gains In Volatile Markets?
In today's chaotic marketplace, the biggest gains will come from some currently-small companies that pass by older, larger businesses still stuck in a pre-pandemic world. The trick is figuring out which small caps will be tomorrow's winners. That's why StockWire News has put together a special Wealth Building Report, highlighting 3 small cap stocks set to soar in 2023.
Click here for full details and to join for free.
Sponsored
There are 2 analysts who have given it a hold rating, whereas 2 have given it a buy rating. Brokers who have rated the stock have averaged $24.00 as their price target over the next twelve months.
With the price target enhanced from $28 to $37, Canaccord Genuity Upgraded its rating from Hold to Buy for AngioDynamics Inc. (NASDAQ: ANGO)., while ‘Raymond James’ rates the stock as ‘Strong Buy’.
In other news, Helsel Dave, SVP Global Operations and R&D sold 4,633 shares of the company’s stock on Jan 31. The stock was sold for $59,997 at an average price of $12.95. Upon completion of the transaction, the SVP Global Operations and R&D now directly owns 19,189 shares in the company, valued at $0.22 million. An SEC document containing details of the transaction can be found on the SEC’s website. On Oct 12, EVP and CFO Trowbridge Stephen A bought 1,083 shares of the business’s stock. A total of $14,967 was incurred on buying the stock at an average price of $13.82. This leaves the insider owning 89,581 shares of the company worth $1.02 million. Insiders disposed of 57,342 shares of company stock worth roughly $0.65 million over the past 1 year. A total of 3.10% of the company’s stock is owned by insiders.
There have been several recent changes in the stakes of large investors in ANGO stock. A new stake in AngioDynamics Inc. shares was purchased by NORGES BANK during the first quarter worth $4,459,000. D. E. SHAW & CO., INC. invested $2,279,000 in shares of ANGO during the first quarter. In the first quarter, QUBE RESEARCH & TECHNOLOGIES LTD acquired a new stake in AngioDynamics Inc. valued at approximately $1,045,000. GRAHAM CAPITAL MANAGEMENT, L.P. acquired a new stake in ANGO for approximately $860,000. MARSHALL WACE, LLP purchased a new stake in ANGO valued at around $820,000 in the second quarter. In total, there are 228 active investors with 96.30% ownership of the company’s stock.
Thursday morning saw AngioDynamics Inc. (NASDAQ: ANGO) opened at $11.47. During the past 12 months, AngioDynamics Inc. has had a low of $11.35 and a high of $24.87. As of last week, the company has a debt-to-equity ratio of 0.12, a current ratio of 2.20, and a quick ratio of 1.30. The fifty day moving average price for ANGO is $13.17 and a two-hundred day moving average price translates $17.07 for the stock.
The latest earnings results from AngioDynamics Inc. (NASDAQ: ANGO) was released for Nov, 2022. According to the Medical Instruments & Supplies Company, earnings per share came in at $0.01, beating analysts’ expectations of -$0.01 by 0.02. This compares to -$0.21 EPS in the same period last year. The net profit margin was -10.00% and return on equity was -7.80% for ANGO. The company reported revenue of $85.43 million for the quarter, compared to $78.28 million a year earlier. Comparatively to last year’s same quarter, the company’s quarterly revenue rose 9.13 percent. For the current quarter, analysts expect ANGO to generate $83.19M in revenue.
AngioDynamics Inc.(ANGO) Company Profile
AngioDynamics, Inc. designs, manufactures, and sells various medical, surgical, and diagnostic devices used by professional healthcare providers for the treatment of peripheral vascular disease and vascular access; and for use in oncology and surgical settings in the United States and internationally. The company provides NanoKnife ablation systems for the surgical ablation of soft tissues; solero microwave tissue ablation systems; and radiofrequency ablation products for ablating solid cancerous or benign tumors. It also offers BioSentry tract sealant systems, IsoLoc Endorectal Balloon’s, alatus vaginal balloon packing systems, angiographic catheters, guidewires, percutaneous drainage catheters, and coaxial micro-introducer kits. In addition, the company provides endovascular therapies products in the areas of thrombus management, atherectomy, peripheral products (Core), and venous insufficiency. Additionally, the company offers peripherally inserted central catheters, midline catheters, implantable ports, dialysis catheters, and related accessories and supplies that are used primarily to deliver short-term drug therapies, such as chemotherapeutic agents and antibiotics, into the central venous system under the BioFlo, BioFlo Midline, BioFlo PICC, Xcela PICC, PASV, BioFlo Port, SmartPort, Vortex, LifeGuard, BioFlo DuraMax, and DuraMax names. It sells and markets its products to interventional radiologists, interventional cardiologists, vascular surgeons, urologists, interventional and surgical oncologists, and critical care nurses directly, as well as through distributor relationships. The company was founded in 1988 and is headquartered in Latham, New York.
